Daiichi Sankyo/Luitpold Submit Injectafer For Iron Deficiency Anemia
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's U.S. subsidiary Luitpold Pharmaceuticals announced May 14 that it has submitted an NDA for Injectafer (ferric carboxymaltose), an intravenous iron replacement product for iron deficiency anemia
You may also be interested in...
U.S. FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
U.S. FDA's Drug Safety and Risk Advisory Committee meets Feb. 1 to discuss patient deaths in trials of Daiichi Sankyo's U.S. subsidiary Luitpold's Injectafer (ferric carboxymaltose) for treatment of anemia in postpartum patients and those with heavy uterine bleeding
U.S. FDA Panel Mulls Safety Of Luitpold’s Intravenous Iron
U.S. FDA's Drug Safety and Risk Advisory Committee meets Feb. 1 to discuss patient deaths in trials of Daiichi Sankyo's U.S. subsidiary Luitpold's Injectafer (ferric carboxymaltose) for treatment of anemia in postpartum patients and those with heavy uterine bleeding
Advanced Magnetics Reports Positive Phase III Data On Ferumoxytol Iron Replacement Therapy
Firm touts faster administration of IV push delivery versus infusion products for chronic kidney disease patients and plans fourth-quarter NDA.